Skip to main content
SpringerLink
Log in

Vascular Complications in Type 2 Diabetes

  • Chapter
  • First Online:
Obesity and Diabetes

  • 2214 Accesses

Abstract

It has long been recognized that diabetes is associated with a high cardiovascular risk, although this is not the same in all patients. Diabetes frequently coexists with other risk factors that will enhance this cardiovascular risk, including hypertension, dyslipidemia, and platelet dysfunction. Treatment of all these risk factors is essential to lower the risk in both primary and secondary cardiovascular prevention settings. The choice of antidiabetic agent may also impact this risk, as some classes have been shown to decrease cardiovascular mortality and others will increase the risk of hypoglycemia, and may have an impact on cardiovascular events.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abdelaziz HK, Saad M, Pothineni NVK, Megaly M, Potluri R, Saleh M et al (2019) Aspirin for primary prevention of cardiovascular events. J Am Coll Cardiol 73(23):2915–2929

    Article  PubMed  Google Scholar 

  • ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr et al (2010a) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362(17):1575–1585

    Article  CAS  Google Scholar 

  • ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA et al (2010b) Effect of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362(17):1563–1574

    Article  Google Scholar 

  • Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 258(24):2545–2559

    Google Scholar 

  • ADVANCE Study Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572

    Article  Google Scholar 

  • Afkarian M, Katz R, Bansal N, Correa A, Kestenbaum B, Himmelfarb J et al (2016) Diabetes, kidney disease, and cardiovascular outcomes in the Jackson Heart Study. Clin J Am Soc Nephrol 11(8):1384–1391

    Article  PubMed  PubMed Central  Google Scholar 

  • American Diabetes Association (2020) Standards of medical care in diabetes—2020. Diabetes Care 43(Suppl 1):S1–S204

    Google Scholar 

  • Antithromobitc Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J et al (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373(9678):1849–1860

    Article  CAS  Google Scholar 

  • Beckett NS, Peters R, Fletcher AE, Staessen JA, Jiu L, Dumitrascu D et al (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358(18):1887–1898

    Article  CAS  PubMed  Google Scholar 

  • Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB et al (2019a) Effects of eicosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol 73(22):2791–2802

    Article  CAS  PubMed  Google Scholar 

  • Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K et al (2019b) Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet 394(10204):1169–1180

    Article  CAS  PubMed  Google Scholar 

  • Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q et al (2018) First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 11:CD008170

    PubMed  Google Scholar 

  • Chen-Ku CH, Gonzalez-Galvez G, Vasquez M, Fuente G, Nakazone MA, Silva Giordano AI et al (2019) Vascular complications in patients with type 2 diabetes: prevalence and comorbidities in 6 countries of Latin America (a cohort of the DISCOVER study program). Endocr Pract 25(10):994–1002

    Article  PubMed  Google Scholar 

  • Cholesterol Treatment Trialists’ (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J et al (2008) Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371(9607):117–125

    Article  CAS  Google Scholar 

  • Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial. Lancet 364(9435):686–696

    Article  CAS  Google Scholar 

  • Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374):2005–2016

    Article  PubMed  CAS  Google Scholar 

  • Consentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V et al (2019) ESC guidelines on diabetes, pre-diabetes and cardiovascular disease developed in collaboration with the EASD. Eur Heart J 34:1–69

    Google Scholar 

  • Costa J, Borges M, David C, Vaz Carneiro A (2006) Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332(7550):1115–1124

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • D’Elia L, Strazzullo P (2018) Excess body weight, insulin resistance and isolated systolic hypertension: potential pathophysiological links. High Blood Press Cardiovasc Prev 25(1):17–23

    Article  PubMed  CAS  Google Scholar 

  • Dal Canto E, Ceriello E, Rydén L, Ferrini M, Hansen TB, Schnell O et al (2019) Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 26(2_suppl):25–32

    Article  PubMed  Google Scholar 

  • Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V (2003) Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 26(5):1485–1489

    Article  PubMed  Google Scholar 

  • Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 366(9493):1279–1289

    Article  CAS  PubMed  Google Scholar 

  • Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360(2):129–139

    Article  CAS  PubMed  Google Scholar 

  • Elliott RH, Mathews VB, Rudnicka C, Schlaich MP (2016) Is it time to think about the sodium glucose co-transporter 2 sympathetically? Nephrology 21(4):286–294

    Article  CAS  PubMed  Google Scholar 

  • Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A (2015) Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313(6):603–615

    Article  PubMed  CAS  Google Scholar 

  • Erqou S, Lee CT, Suffoletto M, Echuoffo-Tcheugui JB, de Boer RA, van Melle JP et al (2013) Association between glycated hemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis. Eur J Heart Fail 15(2):185–193

    Article  CAS  PubMed  Google Scholar 

  • Ferreiro JL, Angiolillo DJ (2011) Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation 123(7):798–813

    Article  PubMed  Google Scholar 

  • Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348(5):383–393

    Article  PubMed  Google Scholar 

  • Gaede P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH et al (2016) Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 59(11):2298–2307

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA et al (2019) Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary. Endocr Pract 25(1):69–100

    Article  PubMed  Google Scholar 

  • Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121–130

    Article  CAS  PubMed  Google Scholar 

  • Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Spinar J et al (2018) Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International trial). Circulation 137(15):1571–1582

    Article  CAS  PubMed  Google Scholar 

  • Grundy SM, Stone NJ, Baiely AL, Beam C, Birtcher KK, Blumenthal RS et al (2019a) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinial practice guidelines. Circulation 139(25):e1082–e1143

    PubMed  Google Scholar 

  • Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al (2019b) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation 139(25):e1082–e1143

    PubMed  Google Scholar 

  • Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339(4):229–234

    Article  CAS  PubMed  Google Scholar 

  • Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones CP et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519–1529

    Article  CAS  PubMed  Google Scholar 

  • Holman RR, Paul SK, Bethel MA, Mathews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 395(15):1577–1589

    Article  Google Scholar 

  • Hu F, Stamper MJ, Solomon CG, Liu S, Willett WC, Speizer FE et al (2001) The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow up. Arch Intern Med 161(14):1717–1723

    Article  CAS  PubMed  Google Scholar 

  • Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M (2016) Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev 11:CD009753

    PubMed  Google Scholar 

  • Jia G, Hill MA, Sowers JR (2018) Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circa Res 122(4):624–638

    Article  CAS  Google Scholar 

  • Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355(23):2427–2443

    Article  CAS  PubMed  Google Scholar 

  • Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR et al (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500):1849–1861

    Article  CAS  PubMed  Google Scholar 

  • Kosiborod M, Inzucchi SE, Krumholz HM, Xiao L, Jones PG, Fiske S et al (2008) Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measures of risk. Circulation 117(8):1018–1027

    Article  CAS  PubMed  Google Scholar 

  • LaRosa JC, Deedwania PC, Shepherd J, Wenger NK, Greten H, DeMicco DA et al (2010) Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets (TNT) trial). Am J Cardiol 105(3):283–287

    Article  CAS  PubMed  Google Scholar 

  • Lee YB, Han K, Kim B, Lee SE, Jun JE, Ahn J et al (2019) Risk of early mortality and cardiovascular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide study. Cardiovasc Diabetol 18(1):157

    Article  PubMed  PubMed Central  Google Scholar 

  • Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijins HJ (2010) Redifining clinical risk stratificaction for predicting stroke and atherothromoboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2):263–272

    Article  PubMed  Google Scholar 

  • Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R et al (2007) Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the LOOK AHEAD trial. Diabetes Care 30(6):1374–1383

    Article  Google Scholar 

  • Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA et al (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369(2):145–154

    Article  CAS  Google Scholar 

  • Low Wang CC, Hess CN, Hiatt WR, Goldfine AB (2016) Atherosclerotic cardiovascular disease and heart failure in type 2 diabetes—mechanisms, management, and clinical consideration. Circulation 133(24):2459–2502

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Makrilakis K, Liatis S (2017) Cardiovascular screening for the asymptomatic patient with diabetes: more cons than pros. J Diabetes Res 2017:8927473

    Article  PubMed  PubMed Central  Google Scholar 

  • Malmberg K (1997) Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314(7093):1512–1515

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K et al (2005) Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26(7):650–661

    Article  CAS  PubMed  Google Scholar 

  • Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA et al (2016a) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311–322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA et al (2016b) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844

    Article  CAS  PubMed  Google Scholar 

  • Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377(8):723–732

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008

    Article  CAS  PubMed  Google Scholar 

  • Miksztowicz V, Lucero D, Zago V, Cacciagiú L, Lopez G, Gonzalez-Ballerga E et al (2012) Hepatic lipase activity is increased in non-alcoholic fatty liver disease beyond insulin resistance. Diabetes Metab Res Rev 28(6):535–541

    Article  CAS  PubMed  Google Scholar 

  • Mohammedi K, Woodward M, Hirakawa Y, Zoungas S, Williams B, Lisheng L et al (2016) Microvascular and macrovascular disease and risk for major peripheral artery disease in patients with type 2 diabetes mellitus. Diabetes Care 39(101):1796–1803

    Article  CAS  PubMed  Google Scholar 

  • Nathan DM, Clearly PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353(25):2643–2653

    Article  PubMed  Google Scholar 

  • Nativel M, Potier L, Alexandre L, Baillet- Blanco L, Ducasse E, Velho G et al (2018) Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. Cardiovasc Diabetol 17(1):138

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M et al (2009) Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20(8):1813–1821

    Article  PubMed  PubMed Central  Google Scholar 

  • Nuryani N, Ling SS, Nguyen HT (2012) Electrocardiographic signals and swarm-based support vector machine for hypoglycemia detection. Ann Biomed Eng 40(4):934–945

    Article  PubMed  Google Scholar 

  • ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367(4):319–328

    Article  CAS  Google Scholar 

  • Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306

    Article  CAS  PubMed  Google Scholar 

  • Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM et al (2018) Risk factors, mortality and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 379(7):633–644

    Article  PubMed  Google Scholar 

  • Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373(9677):1765–1772

    Article  CAS  PubMed  Google Scholar 

  • Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM et al (2010) Epidemiologic relationships between A1c and all-cause mortality during a median of 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33(5):983–990

    Article  PubMed  PubMed Central  Google Scholar 

  • Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ et al (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized controlled trial. JAMA 322(12):1155–1166

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, Del Prato S, Ji L, Sadikot SM, Herman WH, Amiel SA, Kaplan LM, Taroncher-Oldenburg G, Cummings DE, Delegates of the 2nd Diabetes Surgery Summit (2017) Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Obes Surg 27(1):2–21

    Article  PubMed  Google Scholar 

  • Sabanayagam C, Chee ML, Banu R, Cheng CY, Lim SC, Tai ES et al (2019) Association of diabetic retinopathy and diabetic kidney disease with all cause and cardiovascular mortality in multiethnic Asian population. JAMA Netw Open 2(3):e191540

    Article  PubMed  PubMed Central  Google Scholar 

  • Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM et al (2017) Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumabon glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomized controlled trial. Lancet Diabetes Endocrinol 5(12):941–950

    Article  CAS  PubMed  Google Scholar 

  • Saxena T, Ali AO, Saxena M (2018) Pathophysiology of essential hypertension: an update. Exp Rev Cardiovasc Ther 16(12):879–887

    Article  CAS  Google Scholar 

  • Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA et al (2017) Bariatric surgery versus intensive medical therapy for diabetes—5 year outcomes. N Engl J Med 376(7):541–551

    Article  Google Scholar 

  • Schneider C, Coll B, Jick SS, Meier CR (2016) Doubling of serum creatinine and the risk of cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes mellitus: a cohort study. Clin Epidemiol 8:177–184

    PubMed  PubMed Central  Google Scholar 

  • Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P et al (2014) Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130(18):1579–1588

    Article  CAS  PubMed  Google Scholar 

  • Selvin E, Erlinger TP (2004) Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 110(61):738–743

    Article  PubMed  Google Scholar 

  • Stahel P, Xiao C, Hegele RA, Lewis GF (2018) The atherogenic dyslipidemia complex and novel approaches to cardiovascular disease prevention in diabetes. Can J Cardiol 34(5):595–604

    Article  PubMed  Google Scholar 

  • Steg G, Bhatt DL, Wilson P, D’Agostino R, Ohman EM, Röther J et al (2007) One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297(11):1197–1206

    Article  CAS  PubMed  Google Scholar 

  • The Emerging Risk Factor Collaboration, Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS et al (2015) Association of cardiometabolic multimorbidity with mortality. JAMA 314(1):52–60

    Article  CAS  Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998a) Intensive blood glucose control with sulphonylureas or insulin compared to conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853

    Article  Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998b) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865

    Article  Google Scholar 

  • UKPDS (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 317(7160):713–720

    Article  Google Scholar 

  • Uzu T (2017) Salt and hypertension in diabetes. Diabetol Int 8(2):154–159

    Article  PubMed  PubMed Central  Google Scholar 

  • Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP et al (2017) Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 5(11):887–897

    Article  PubMed  Google Scholar 

  • Wang F, Han L, Hu D (2017) Fasting insulin, insulin resistance and risk of hypertension in the general population: a meta-analysis. Clin Chim Acta 464:57–63

    Article  CAS  PubMed  Google Scholar 

  • Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/NMA/PCNA Guideline for the prevention, detection evaluation and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension 71(19):e127–e248

    Google Scholar 

  • Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357

    Article  CAS  PubMed  Google Scholar 

  • Zamora M, Villena JA (2019) Contribution of impaired insulin signaling to the pathogenesis of diabetic cardiomyopathy. Int J Mol Sci 20(11):E2833

    Article  PubMed  CAS  Google Scholar 

  • Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT et al (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385(9982):2067–2076

    Article  CAS  PubMed  Google Scholar 

  • Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31–39

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Department, Hospital San Juan de Dios, Caja Costarricense de Seguro Social, San José, Costa Rica

    Chih Hao Chen Ku

  2. Clinical Pharmacology and Toxicology Department, University of Costa Rica, San José, Costa Rica

    Chih Hao Chen Ku

Authors
  1. Chih Hao Chen Ku
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chih Hao Chen Ku .

Editor information

Editors and Affiliations

  1. Hospital das Clinicas, Sao Paulo University Medical School, Sao Paulo, Brazil

    Joel Faintuch

  2. Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Salomão Faintuch

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ku, C.H.C. (2020). Vascular Complications in Type 2 Diabetes. In: Faintuch, J., Faintuch, S. (eds) Obesity and Diabetes. Springer, Cham. https://doi.org/10.1007/978-3-030-53370-0_37

Download citation

Publish with us

Policies and ethics

Search

Navigation